Cases & Deals

  • Home
  • Practices
  • MindRank collaborates on development of clinical-stage small molecule therapeutics for treating of metabolic disorders

Share

MindRank collaborates on development of clinical-stage small molecule therapeutics for treating of metabolic disorders

May 2025

Client(s) MindRank AI Ltd.

Jones Day is advising MindRank AI Ltd., an artificial intelligence (AI)-powered drug discovery company, on IP licensing strategies to facilitate strategic collaborations and partnerships aimed at advancing both clinical development and commercial objectives for its small molecule therapeutics for use in the treatment of various metabolic disorders.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.